Heading 2



Alibion was born to bring new drug discoveries out of academic labs and closer to patients. We accelerate the development of therapeutics through early stages. Our efforts are focused on identifying promising novel therapeutics and pooling the necessary resources to drive these compounds out of the labs and into late-stage development. 

Alibion has stopped operations since December 2020. 



© Alibion AG 2018